New updates on TROP2-directed antibody-drug conjugates (ADCs) highlighted progress across lung and breast cancer programs and pointed to areas for improvement in targeting, dosing, and next-line positioning. The coverage consolidated multiple readouts and development updates for the class. Across the included pipeline, TROP2 ADCs are being evaluated as more active options in settings where survival and disease control remain constrained. The updates also reflect the continuing focus on broadening indication scope while refining safety and efficacy. For biotech teams, the developments reinforce that ADC differentiation—payload selection, linker stability, and patient selection—continues to be a central competitive lever.